

**UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.)*

Emergent BioSolutions Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

29089Q 10 5

(CUSIP Number)

March 8, 2007

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Advent Private Equity Fund III "A" Limited Partnership

2. Check the Appropriate Box if a Member of a Group (See Instructions)

- (a)
- (b)

3. SEC Use Only

4. Citizenship or Place of Organization
England

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power

6. Shared Voting Power
3,636,801 (includes both 468,355 shares of common stock owned individually by Advent Private Equity Fund III "A" Limited Partnership and 3,168,446 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)
-
7. Sole Dispositive Power
468,355
-
8. Shared Dispositive Power
-
9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801
-
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
-
11. Percent of Class Represented by Amount in Row (9)
14.25%
-
12. Type of Reporting Person (See Instructions)
PN
-

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Advent Private Equity Fund III "B" Limited Partnership
-
2. Check the Appropriate Box if a Member of a Group (See Instructions)
- (a) x
-
- (b) o
-
3. SEC Use Only
-
4. Citizenship or Place of Organization
England
-

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power
-
6. Shared Voting Power
3,636,801 (includes both 229,497 shares of common stock owned individually by Advent Private Equity Fund III "B" Limited Partnership and 3,407,304 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)
-
7. Sole Dispositive Power
229,497
-

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)
14.25%

12. Type of Reporting Person (See Instructions)
PN

3

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Advent Private Equity Fund III "C" Limited Partnership

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization
England

5. Sole Voting Power

6. Shared Voting Power

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

3,636,801 (includes both 64,018 shares of common stock owned individually by Advent Private Equity Fund III "C" Limited Partnership and 3,572,783 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)

7. Sole Dispositive Power
64,018

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)
14.25%

12. Type of Reporting Person (See Instructions)
PN

4

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Advent Private Equity Fund III "D" Limited Partnership

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) x

(b) o

3. SEC Use Only

4. Citizenship or Place of Organization
England

5. Sole Voting Power

6. Shared Voting Power

3,636,801 (includes both 125,921 shares of common stock owned individually by Advent Private Equity Fund III "D" Limited Partnership and 3,510,880 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)

7. Sole Dispositive Power
125,921

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

11. Percent of Class Represented by Amount in Row (9)
14.25%

12. Type of Reporting Person (See Instructions)
PN

5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Advent Private Equity Fund III GmbH & CO KG

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) x

(b) o

3. SEC Use Only

4. Citizenship or Place of Organization
Germany

5. Sole Voting Power

6. Shared Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With

3,636,801 (includes both 18,118 shares of common stock owned individually by Advent Private Equity Fund III GmbH & CO KG and 3,618,683 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)

7. Sole Dispositive Power
18,118

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

11. Percent of Class Represented by Amount in Row (9)
14.25%

12. Type of Reporting Person (See Instructions)
OO

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Advent Private Equity Fund III Affiliates

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) x
(b) o

3. SEC Use Only

4. Citizenship or Place of Organization
England

5. Sole Voting Power

6. Shared Voting Power
3,636,801 (includes both 15,098 shares of common stock owned individually by Advent Private Equity Fund III Affiliates and 3,621,703 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7. Sole Dispositive Power
15,098

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

11. Percent of Class Represented by Amount in Row (9)
14.25%

12. Type of Reporting Person (See Instructions)
PN

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Advent Management III Limited Partnership

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) x
(b) o

3. SEC Use Only

4. Citizenship or Place of Organization
Scotland

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power
	6.	Shared Voting Power 3,636,801 (includes both 4,530 shares of common stock owned individually by Advent Management III Limited Partnership and 3,632,271 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)
	7.	Sole Dispositive Power 4,530
	8.	Shared Dispositive Power
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,636,801	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="radio"/>	
11.	Percent of Class Represented by Amount in Row (9) 14.25%	
12.	Type of Reporting Person (See Instructions) PN	

CUSIP No. 29089Q 10 5

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Merlin Biosciences Fund Limited Partnership	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)	
	(a)	<input checked="" type="radio"/>
	(b)	<input type="radio"/>
3.	SEC Use Only	
4.	Citizenship or Place of Organization Jersey	

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power
	6.	Shared Voting Power 3,636,801 (includes both 498,722 shares of common stock owned individually by Merlin Biosciences Fund Limited Partnership and 3,138,079 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)

7. Sole Dispositive Power
498,722
-
8. Shared Dispositive Power
-
9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801
-
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
-
11. Percent of Class Represented by Amount in Row (9)
14.25%
-
12. Type of Reporting Person (See Instructions)
PN
-

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Merlin Biosciences Fund GbR
-
2. Check the Appropriate Box if a Member of a Group (See Instructions)
- (a) x
- (b) o
-
3. SEC Use Only
-
4. Citizenship or Place of Organization
Germany
-
5. Sole Voting Power
-
6. Shared Voting Power
3,636,801 (includes both 29,972 shares of common stock owned individually by Merlin Biosciences Fund GbR and 3,606,829 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)
-
7. Sole Dispositive Power
29,972
-
8. Shared Dispositive Power
-
9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801
-

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
-
11. Percent of Class Represented by Amount in Row (9)
14.25%
-
12. Type of Reporting Person (See Instructions)
OO
-

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
J.P. Morgan Partners (BHCA), L.P.
-

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) x

(b) o

3. SEC Use Only
-

4. Citizenship or Place of Organization
Delaware
-

5. Sole Voting Power
-

6. Shared Voting Power

3,636,801 (includes both 415,381 shares of common stock owned individually by J.P. Morgan Partners (BHCA), L.P. and 3,221,420 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)

7. Sole Dispositive Power
415,381
-

8. Shared Dispositive Power
-

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801
-

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
-

11. Percent of Class Represented by Amount in Row (9)
14.25%
-

12. Type of Reporting Person (See Instructions)
PN
-

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
J.P. Morgan Partners Global Investors, L.P.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) x

(b) o

3. SEC Use Only

4. Citizenship or Place of Organization
Delaware

5. Sole Voting Power

6. Shared Voting Power

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

3,636,801 (includes both 94,399 shares of common stock owned individually by J.P. Morgan Partners Global Investors, L.P. and 3,542,402 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)

7. Sole Dispositive Power
94,399

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

11. Percent of Class Represented by Amount in Row (9)
14.25%

12. Type of Reporting Person (See Instructions)
PN

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
J.P. Morgan Partners Global Investors (Cayman), L.P.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) x

(b) o

3. SEC Use Only

4. Citizenship or Place of Organization

Cayman Islands

5. Sole Voting Power

6. Shared Voting Power

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

3,636,801 (includes both 47,652 shares of common stock owned individually by J.P. Morgan Partners Global Investors (Cayman), L.P. and 3,589,149 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)

7. Sole Dispositive Power

47,652

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person

3,636,801

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

11. Percent of Class Represented by Amount in Row (9)

14.25%

12. Type of Reporting Person (See Instructions)

PN

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)

S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

J.P. Morgan Partners Global Investors A, L.P.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) x

(b) o

3. SEC Use Only

4. Citizenship or Place of Organization

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power
	6.	Shared Voting Power 3,636,801 (includes both 13,689 shares of common stock owned individually by J.P. Morgan Partners Global Investors A, L.P. and 3,623,112 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)
	7.	Sole Dispositive Power 13,689
	8.	Shared Dispositive Power
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,636,801	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="radio"/>	
11.	Percent of Class Represented by Amount in Row (9) 14.25%	
12.	Type of Reporting Person (See Instructions) PN	

CUSIP No. 29089Q 10 5

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON J.P. Morgan Partners Global Investors (Cayman) II, L.P.	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)	
	(a)	<input checked="" type="checkbox"/>
	(b)	<input type="checkbox"/>
3.	SEC Use Only	
4.	Citizenship or Place of Organization Cayman Islands	

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power
---	----	-------------------

6. Shared Voting Power
3,636,801 (includes both 5,320 shares of common stock owned individually by J.P. Morgan Partners Global Investors (Cayman) II, L.P. and 3,631,481 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)
-
7. Sole Dispositive Power
5,320
-
8. Shared Dispositive Power
-
9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801
-
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
-
11. Percent of Class Represented by Amount in Row (9)
14.25%
-
12. Type of Reporting Person (See Instructions)
PN
-

15

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
J.P. Morgan Partners Global Investors (Selldown), L.P.
-
2. Check the Appropriate Box if a Member of a Group (See Instructions)
- (a) x
- (b) o
-
3. SEC Use Only
-
4. Citizenship or Place of Organization
Delaware
-

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power
-
6. Shared Voting Power
3,636,801 (includes both 33,714 shares of common stock owned individually by J.P. Morgan Partners Global Investors (Selldown), L.P. and 3,603,087 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)
-
7. Sole Dispositive Power
33,714
-

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)
14.25%

12. Type of Reporting Person (See Instructions)
PN

16

CUSIP No. 29089Q 10 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
J.P. Morgan Partners Global Investors (Selldown) II, L.P.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization
Delaware

5. Sole Voting Power

6. Shared Voting Power

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

3,636,801 (includes both 117,054 shares of common stock owned individually by J.P. Morgan Partners Global Investors (Selldown) II, L.P. and 3,519,747 shares of common stock issued to other investment funds affiliated with Advent Venture Partners LLP, Apax WW Nominees LTD, J.P. Morgan Partners, LLC and The Merlin Biosciences Funds, all of which are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.)

7. Sole Dispositive Power
117,054

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,636,801

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)
14.25%

12. Type of Reporting Person (See Instructions)
PN

17

Item 1.

- (a) Name of Issuer
Emergent BioSolutions Inc.
-
- (b) Address of Issuer's Principal Executive Offices
300 Professional Drive
Suite 250
Gaithersburg, Maryland 20879
-

Item 2.

- (a) Name of Person Filing
Advent Private Equity Fund III "A" Limited Partnership;
Advent Private Equity Fund III "B" Limited Partnership;
Advent Private Equity Fund III "C" Limited Partnership;
Advent Private Equity Fund III "D" Limited Partnership;
Advent Private Equity Fund III GMBH & CO KG.;
Advent Private Equity Fund III Affiliates;
Advent Management III Limited Partnership;
Merlin Biosciences Fund Limited Partnership;
Merlin Biosciences Fund GbR;
J.P. Morgan Partners (BHCA), L.P.*;
J.P. Morgan Partners Global Investors, L.P.*;
J.P. Morgan Partners Global Investors (Cayman), L.P.*;
J.P. Morgan Partners Global Investors A, L.P.*;
J.P. Morgan Partners Global Investors (Cayman) II, L.P.*;
J.P. Morgan Partners Global Investors (Selldown), L.P.*; and
J.P. Morgan Partners Global Investors (Selldown) II, L.P.
-
- (b) Address of Principal Business Office or, if none, Residence
Advent Private Equity Fund III "A" Limited Partnership
25 Buckingham Gate
London SW1E 6LD
United Kingdom
- Advent Private Equity Fund III "B" Limited Partnership
25 Buckingham Gate
London SW1E 6LD
United Kingdom

* Supplemental information relating to the ownership and control of the J.P. Morgan Partners entities filing this statement is included in Exhibit 2 attached hereto.

18

Advent Private Equity Fund III "C" Limited Partnership
25 Buckingham Gate
London SW1E 6LD
United Kingdom

Advent Private Equity Fund III "D" Limited Partnership 25 Buckingham Gate
London SW1E 6LD
United Kingdom

Advent Private Equity Fund III GMBH & CO KG

Theresienstrasse 6
Munich 80333
Germany

Advent Private Equity Fund III Affiliates
25 Buckingham Gate
London SW1E 6LD
United Kingdom

Advent Management III Limited Partnership
50 Lothian Road, Festival Square
Edinburgh EH3 9WJ
United Kingdom

Merlin Biosciences Fund Limited Partnership
La Motte Chambers
La Motte Street
St. Helier
Jersey JE1 1BJ
United Kingdom

Merlin Biosciences Fund GbR
La Motte Chambers
La Motte Street
St. Helier
Jersey JE1 1BJ
United Kingdom

J.P. Morgan Partners (BHCA), L.P.**
c/o J.P. Morgan Partners, L.L.C.
270 Park Avenue

** See also supplemental information relating to the principal business office included in Exhibit 2 attached hereto.

New York, New York 10017
United States

J.P. Morgan Partners Global Investors, L.P.**
c/o J.P. Morgan Partners, L.L.C.
270 Park Avenue
New York, New York 10017
United States

J.P. Morgan Partners Global Investors (Cayman), L.P.**
c/o J.P. Morgan Partners, L.L.C.
270 Park Avenue
New York, New York 10017
United States

J.P. Morgan Partners Global Investors A, L.P.**
c/o J.P. Morgan Partners, L.L.C.
270 Park Avenue
New York, New York 10017
United States

J.P. Morgan Partners Global Investors (Cayman) II, L.P.**
c/o J.P. Morgan Partners, L.L.C.
270 Park Avenue
New York, New York 10017
United States

J.P. Morgan Partners Global Investors (Selldown), L.P.**
c/o J.P. Morgan Partners, L.L.C.
270 Park Avenue
New York, New York 10017
United States

J.P. Morgan Partners Global Investors (Selldown) II, L.P.**

c/o J.P. Morgan Partners, L.L.C.
270 Park Avenue
New York, New York 10017
United States

- (c) Citizenship
The citizenship of each of the funds is as follows:

Advent Private Equity Fund III “A” Limited Partnership (England);
Advent Private Equity Fund III “B” Limited Partnership (England);

20

Advent Private Equity Fund III “C” Limited Partnership (England);
Advent Private Equity Fund III “D” Limited Partnership (England);
Advent Private Equity Fund III GMBH & CO KG. (Germany);
Advent Private Equity Fund III Affiliates (England);
Advent Management III Limited Partnership (Scotland);
Merlin Biosciences Fund Limited Partnership (Jersey);
Merlin Biosciences Fund GbR (Germany);
J.P. Morgan Partners (BHCA), L.P. (Delaware);
J.P. Morgan Partners Global Investors, L.P. (Delaware);
J.P. Morgan Partners Global Investors (Cayman), L.P. (Cayman Islands);
J.P. Morgan Partners Global Investors A, L.P. (Delaware);
J.P. Morgan Partners Global Investors (Cayman) II, L.P. (Cayman Islands);
J.P. Morgan Partners Global Investors (Selldown), L.P. (Delaware); and
J.P. Morgan Partners Global Investors (Selldown) II, L.P. (Delaware);

- (d) Title of Class of Securities
Common Stock, \$0.001 par value
-

- (e) CUSIP Number
29089Q 10 5
-

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Not applicable.

21

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:
3,636,801 shares

(b) Percent of class:
14.25%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote
Not applicable.

(ii) Shared power to vote or to direct the vote
3,636,801 shares***

(iii) Sole power to dispose or to direct the disposition of
Advent Private Equity Fund III "A" Limited Partnership owns 468,355 shares;
Advent Private Equity Fund III "B" Limited Partnership owns 229,497 shares;
Advent Private Equity Fund III "C" Limited Partnership owns 64,018 shares;
Advent Private Equity Fund III "D" Limited Partnership owns 125,921 shares;
Advent Private Equity Fund III GMBH & CO KG. owns 18,118 shares;
Advent Private Equity Fund III Affiliates owns 15,098 shares;
Advent Management III Limited Partnership owns 4,530 shares;
Merlin Biosciences Fund Limited Partnership owns 498,722 shares;
Merlin Biosciences Fund GbR owns 29,972 shares;
J.P. Morgan Partners (BHCA), L.P. owns 415,381 shares;
J.P. Morgan Partners Global Investors, L.P. owns 94,399 shares;
J.P. Morgan Partners Global Investors (Cayman), L.P. owns 47,652 shares;
J.P. Morgan Partners Global Investors A, L.P. owns 13,689 shares;
J.P. Morgan Partners Global Investors (Cayman) II, L.P. owns 5,320 shares;
J.P. Morgan Partners Global Investors (Selldown), L.P. owns 33,714 shares; and
J.P. Morgan Partners Global Investors (Selldown) II, L.P. owns 117,054 shares;

(iv) Shared power to dispose or to direct the disposition of
None

*** All of the Reporting Persons and APAX WW Nominees LTD are party to a voting agreement with BioPharm, L.L.C., whereby the parties have agreed to vote all shares of such common stock owned by the parties in the same manner and to the same extent as BioPharm, L.L.C.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

23

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 8, 2007

ADVENT PRIVATE EQUITY FUND III "A" LIMITED PARTNERSHIP

By: /s/ Shahzad Malik

Name: Shahzad Malik

Title: Attorney-In-Fact

ADVENT PRIVATE EQUITY FUND III "B" LIMITED PARTNERSHIP

By: /s/ Shahzad Malik

Name: Shahzad Malik

Title: Attorney-In-Fact

ADVENT PRIVATE EQUITY FUND III "C" LIMITED PARTNERSHIP

By: /s/ Shahzad Malik

Name: Shahzad Malik

Title: Attorney-In-Fact

ADVENT PRIVATE EQUITY FUND III "D" LIMITED PARTNERSHIP

By: /s/ Shahzad Malik

Name: Shahzad Malik

Title: Attorney-In-Fact

24

ADVENT PRIVATE EQUITY FUND III GMBH & CO. KG

By: /s/ Shahzad Malik

Name: Shahzad Malik

Title: Attorney-In-Fact

ADVENT PRIVATE EQUITY FUND III AFFILIATES

By: /s/ Shahzad Malik

Name: Shahzad Malik

Title: Attorney-In-Fact

ADVENT MANAGEMENT III LIMITED PARTNERSHIP

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: Attorney-In-Fact

MERLIN BIOSCIENCES FUND LIMITED PARTNERSHIP

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: Attorney-In-Fact

MERLIN BIOSCIENCES FUND GBR

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: Attorney-In-Fact

J.P. MORGAN PARTNERS (BHCA), L.P.

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: Attorney-In-Fact

25

J.P. MORGAN PARTNERS GLOBAL INVESTORS, L.P.

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: Attorney-In-Fact

J.P. MORGAN PARTNERS GLOBAL INVESTORS (CAYMAN), L.P.

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: Attorney-In-Fact

J.P. MORGAN PARTNERS GLOBAL INVESTORS A, L.P.

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: Attorney-In-Fact

J.P. MORGAN PARTNERS GLOBAL INVESTORS (CAYMAN) II, L.P.

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: Attorney-In-Fact

J.P. MORGAN PARTNERS GLOBAL INVESTORS (SELLDOWN), L.P.

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: Attorney-In-Fact

26

By: /s/ Shahzad Malik

Name: Shahzad Malik

Title: Attorney-In-Fact

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: General Partner

By: ADVENT VENTURE PARTNERS LLP, as manager of Advent Management III Limited Partnership

By: /s/ Shahzad Malik
Name: Shahzad Malik
Title: General Partner

3

MERLIN BIOSCIENCES FUND

By: MERLIN GENERAL PARTNER II LIMITED, as general partner of the Merlin Biosciences Fund LP

By: /s/ Denzil Boschat
Name: Denzil Boschat
Title: Director

MERLIN BIOSCIENCES FUND

By: MERLIN GENERAL PARTNER II LIMITED, as managing partner of the Merlin BioSciences Fund Gbr

By: /s/ Denzil Boschat
Name: Denzil Boschat
Title: Director

4

J.P. MORGAN PARTNERS (BHCA), L.P.

By: JPMP MASTER FUND MANAGER, its general partner

By: JPMP CAPITAL CORP, its general partner

By: Panorama Capital, LLC, as Attorney in Fact

By: /s/ Srinivas Akkaraju

Name: Srinivas Akkaraju

Title: Managing Director

J.P. MORGAN PARTNERS GLOBAL INVESTORS, L.P.

By: JPMP GLOBAL INVESTORS, L.P., its general partner

By: JPMP CAPITAL CORP, its general partner

By: Panorama Capital, LLC, as Attorney in Fact

By: /s/ Srinivas Akkaraju

Name: Srinivas Akkaraju

Title: Managing Director

J.P. MORGAN PARTNERS GLOBAL INVESTORS (CAYMAN), L.P.

By: JPMP GLOBAL INVESTORS, L.P., its general partner

By: JPMP CAPITAL CORP, its general partner

By: Panorama Capital, LLC, as Attorney in Fact

By: /s/ Srinivas Akkaraju

Name: Srinivas Akkaraju

Title: Managing Director

J.P. MORGAN PARTNERS GLOBAL INVESTORS A, L.P.

By: JPMP GLOBAL INVESTORS, L.P., its general partner

By: JPMP CAPITAL CORP, its general partner

By: Panorama Capital, LLC, as Attorney in Fact

By: /s/ Srinivas Akkaraju
Name: Srinivas Akkaraju
Title: Managing Director

J.P. MORGAN PARTNERS GLOBAL INVESTORS (CAYMAN) II, L.P.
By: JPMP GLOBAL INVESTORS, L.P., its general partner
By: JPMP CAPITAL CORP, its general partner
By: Panorama Capital, LLC, as Attorney in Fact

By: /s/ Srinivas Akkaraju
Name: Srinivas Akkaraju
Title: Managing Director

J.P. MORGAN PARTNERS GLOBAL INVESTORS (SELLOWN), L.P.
By: JPMP GLOBAL INVESTORS, L.P., its general partner
By: JPMP CAPITAL CORP, its general partner
By: Panorama Capital, LLC, as Attorney in Fact

By: /s/ Srinivas Akkaraju
Name: Srinivas Akkaraju
Title: Managing Director

J.P. MORGAN PARTNERS GLOBAL INVESTORS (SELLOWN) II, L.P.
By: JPMP GLOBAL INVESTORS, L.P., its general partner
By: JPMP CAPITAL CORP, its general partner
By: Panorama Capital, LLC, as Attorney in Fact

By: /s/ Srinivas Akkaraju
Name: Srinivas Akkaraju
Title: Managing Director

Item 2. Identity and Background.

This statement is being filed by J.P. Morgan Partners (BHCA), L.P., a Delaware limited partnership (hereinafter referred to as “JPMP (BHCA)”), whose principal business office is located 270 Park Avenue, New York, New York 10017. JPMP (BHCA) is engaged in the venture capital, private equity and leveraged buyout business. The general partner of JPMP (BHCA) is JPMP Master Fund Manager, L.P., a Delaware limited partnership (hereinafter referred to as “JPMP Master Fund”), whose principal business office is located at the same address as JPMP (BHCA), and is also engaged directly and indirectly (through affiliates) in the venture capital, private equity and leveraged buyout business. As general partner of JPMP (BHCA), JPMP Master Fund may be deemed to beneficially own the shares held by JPMP (BHCA).

This statement is also being filed by J.P. Morgan Partners Global Investors, L.P., a Delaware limited partnership (“JPMP Global”), whose principal place of business is located at the same address as JPMP (BHCA); J.P. Morgan Partners Global Investors “A”, L.P., a Delaware limited partnership (“JPMP Global A”), whose principal place of business is located at the same address as JPMP (BHCA); J.P. Morgan Partners Global Investors (Cayman), L.P., a limited partnership organized under the laws of the Cayman Islands (“JPMP Cayman”), whose principal place of business is located at the same address as JPMP (BHCA); J.P. Morgan Partners Global Investors (Cayman) II, L.P., a limited partnership organized under the laws of the Cayman Islands (“JPMP Cayman II”), whose principal place of business is located at the same address as JPMP (BHCA), J.P. Morgan Partners Global Investors (Selldown), L.P., a Delaware limited partnership, whose principal place of business is located at the same address as JPMP (BHCA) and J.P. Morgan Partners Global Investors (Selldown) II, L.P., a Delaware limited partnership (“JPMP Selldown II” and collectively with JPMP Global, JPMP Global A, JPMP Cayman, JPMP Cayman II, JPMP Selldown and JPMP Selldown II, the “Global Fund Entities”), whose principal place of business is located at the same address as JPMP (BHCA). Each of the Global Fund Entities is also engaged in the venture capital, private equity and leveraged buyout business. The general partner of each of the Global Fund Entities is J.P. Morgan Partners Global Investors, L.P., a Delaware limited partnership (“JPMP Investors”), whose principal place of business is located at the same address as JPMP (BHCA). JPMP Investors is engaged indirectly in the venture capital, private equity and leveraged buyout business as general partner of each of the Global Fund Entities. As general partner of each of the Global Fund Entities, JPMP Investors may be deemed to beneficially own the shares held by the Global Fund Entities.

The general partner of each of JPMP Master Fund and JPMP Investors is JPMP Capital Corp., a New York corporation (hereinafter referred to as “JPMP Capital Corp.”), whose principal business office is located at the same address as JPMP (BHCA), and is also engaged directly and indirectly (through affiliates) in the venture capital, private equity and leveraged buyout business. Set forth in Schedule A hereto and incorporated herein by reference are the names, business addresses, principal occupations and employments of each executive officer and director of JPMP Capital Corp. As the general partner of each of JPMP Master Fund and JPMP Investors, JPMP Capital Corp. may be deemed to beneficially own the shares held by JPMP (BHCA) and the Global Fund Entities.

JPMP Capital Corp. is a wholly owned subsidiary of JPMorgan Chase & Co., a Delaware corporation (hereinafter referred to as “JPMorgan Chase”) which is engaged (primarily through subsidiaries) in the commercial banking business with its principal office located at 270 Park Avenue, New York, New York 10017. Set forth in Schedule B hereto and incorporated herein by reference are the names, business addresses, principal occupations and employments of each executive officer and director of JPMorgan Chase.

SCHEDULE AJPMP CAPITAL CORP.

Executive Officers (1)

Chief Investment Officer	Ina R. Drew*
Managing Director	Joseph S. Bonocore*
Managing Director	Ana Capella Gomez-Acebo*
Managing Director	John C. Wilmot*
Managing Director and Assistant Secretary	Richard Madsen*
Vice President	William T. Williams Jr.*
Vice President and Assistant General Counsel	Judah Shechter*
Vice President and Assistant General Counsel	Elizabeth De Guzman*

Directors (1)

Ina R. Drew*
John C. Wilmot*

(1) Each of whom is a United States citizen

* Principal occupation is employee and/or officer of JPMorgan Chase & Co. Business address is c/o JPMorgan Chase & Co., 270 Park Avenue, New York, NY 10017

SCHEDULE B

JPMORGAN CHASE & CO.
Executive Officers (1)

President and Chief Executive Officer
 Chief Administrative Officer
 Co-Chief Executive Officer, Investment Bank
 Chief Financial Officer
 Director of Human Resources
 Chief Investment Officer
 Head, Commercial Banking
 Head, Strategy and Business Development
 Chief Executive Officer, Treasury &
 Securities Services
 Head, Retail Financial Services
 Chief Executive Officer, Card Services
 Global Head, Asset & Wealth Management
 Co-Chief Executive Officer, Investment Bank
 General Counsel

James Dimon*
 Frank Bisignano*
 Steven D. Black*
 Michael J. Cavanagh*
 John F. Bradley*
 Ina R. Drew*
 Samuel Todd Maclin*
 Jay Mandelbaum*

 Heidi Miller*
 Charles W. Scharf*
 Richard J. Srednicki*
 James E. Staley*
 William T. Winters*
 Stephen M. Cutler*

(1) Each of whom is a United States citizen.

* Principal occupation is employee or officer of JPMorgan Chase & Co. Business address is c/o JPMorgan Chase & Co., 270 Park Avenue, New York, New York 10017.

Directors (1)

Name	Principal Occupation or Employment; Business or Residence Address
John H. Biggs	Former Chairman and CEO TIAA - CREF c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017
Crandall C. Bowles	Chairman and Chief Executive Officer Spring Global US, Inc. c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017
Stephen B. Burke	President Comcast Cable Communications, Inc. c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017
James S. Crown	President Henry Crown and Company c/o JP Morgan Chase & Co. 270 Park Avenue New York, New York 10017
James Dimon	Chief Executive Officer JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017
Ellen V. Futter	President and Trustee American Museum of Natural History c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017
William H. Gray, III	Retired President and Chief Executive Officer The College Fund/UNCF c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017
Laban P. Jackson, Jr.	Chairman and Chief Executive Officer Clear Creek Properties, Inc. c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017
Lee R. Raymond	Chairman of the Board and Chief Executive Officer Exxon Mobil Corporation c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017

John W. Kessler

Owner
John W. Kessler Company
c/o JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017

Robert I. Lipp

Chairman
The St. Paul Travelers Companies, Inc.
c/o JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017

Richard A. Monoogian

Chairman and Chief Executive Officer
Masco Corporation
c/o JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017

David C. Novak

Chairman and Chief Executive Officer
Yum! Brands, Inc.
c/o JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017

William C. Weldon

Chairman and Chief Executive Officer
Johnson & Johnson
c/o JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
